Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01615042 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of Lenalidomide in Patients With Acute Leukemia
A Phase 1 study, sponsored by Mehrdad Abedi, MD.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT01615042: Clinical Trial Phase 1 study, sponsored by Mehrdad Abedi, MD.
NCT01615042 is a Phase 1 study that was terminated before completion, run by Mehrdad Abedi, MD. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01615042, a Phase 1 study, was terminated before completion, sponsored by Mehrdad Abedi, MD.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
Lenalidomide is a drug that alters the immune system and it may also be directly toxic to tumor. Therefore, in theory, it may reduce or prevent the growth of cancer cells or directly kill them. We will be studying how lenalidomide can be used to decrease bone marrow blast cells in preparation for a bone transplant.
Primary Outcome
All patients who receive the study drug will be followed closely and evaluated for toxicity. Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL. Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL. G
Interventions
- DRUG Lenalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2012-08 |
| Est. Completion | 2017-05 |
| Phase | Phase 1 |
Why NCT01615042 stopped before completion
NCT01615042 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which Lenalidomide is the first listed.
NCT01615042 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01615042 about?
NCT01615042 is a clinical study titled "Phase I Study of Lenalidomide in Patients With Acute Leukemia". Lenalidomide is a drug that alters the immune system and it may also be directly toxic to tumor. Therefore, in theory, it may reduce or prevent the growth of cancer cells or directly kill them. We will be studying how lenalidomide can be used to decrease bone marrow blast cells in preparation for a ...
What is the current status of trial NCT01615042?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2012-08. Estimated completion is 2017-05.
What interventions are being tested in trial NCT01615042?
The interventions under investigation include: Lenalidomide (DRUG).
Who is sponsoring clinical trial NCT01615042?
This trial is sponsored by Mehrdad Abedi, MD, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01615042's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia